SCHEMBL10127156

SCHEMBL10127156

CSc1nc(Cl)c(C(N)=O)c(Nc2cccnc2-c2ccccc2)n1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.43
SMN1; SMN2 Q16637 2/20 0.41
NTRK1 P04629 3/20 0.41
RXFP1 Q9HBX9 5/20 0.40
MAPT P10636 3/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 2/20 0.38
HPGD P15428 1/20 0.38
RAB9A P51151 1/20 0.38
MEN1 O00255 1/20 0.38
TP53 P04637 1/20 0.38
BLM P54132 1/20 0.38
KMT2A Q03164 1/20 0.38
PDE4B Q07343 1/20 0.38
HSD17B10 Q99714 1/20 0.38
THRB P10828 1/20 0.37
HTT P42858 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10127169 0.87 MAPT (0.44) PPARGSMN1; SMN2MAPTPOLBALDH1A1
SCHEMBL10127167 0.84 NTRK1 (0.38) PPARGSMN1; SMN2NTRK1RXFP1MAPT
SCHEMBL10127210 0.80 GSK3B (0.44) PPARGMAPT
SCHEMBL10126692 0.80 PPARG (0.47) PPARGRXFP1MAPTPOLBALDH1A1
SCHEMBL10127174 0.78 PPARG (0.42) PPARGSMN1; SMN2NTRK1RXFP1MAPT
SCHEMBL10127142 0.78 PDE4B (0.45) PPARGNTRK1RXFP1MAPTPOLB
SCHEMBL10127011 0.75 ALK (0.46) NTRK1
SCHEMBL10127219 0.75 MAPKAPK2 (0.45) PPARGSMN1; SMN2NTRK1ALDH1A1HPGD
SCHEMBL10127179 0.74 SMN1; SMN2 (0.38) PPARGSMN1; SMN2MAPTPOLBALDH1A1
SCHEMBL10127225 0.73 PPARG (0.40) PPARGSMN1; SMN2MAPTPOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
EP-3009428-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND Astellas Pharma Inc. (JP) 2016-04-20 EP disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed
WO-2010128659-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND アステラス製薬株式会社 (JP) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 PPARG 2536/4885SMN1; SMN2 4467/4885NTRK1 521/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 PPARG 2536/4885SMN1; SMN2 4467/4885NTRK1 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.